Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goodall

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Antimicrobial Chemotherapy|May 1, 1999
Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?P J Easterbrook, R L Goodall, A G Babiker, et al.
Expert Opinion on Drug Safety|March 11, 2024
T-wave morphology abnormalities in the STREAM stage 1 trialGareth Hughes, William J Young, Henry Bern, et al.
AIDS Research and Human Retroviruses|October 9, 1998
Association between a defective CCR-5 gene and progression to disease in HIV infectionP Balfe, Y Churcher, M Penny, et al.
Sexually Transmitted Infections|August 7, 2003
Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital wartsC J N Lacey, R L Goodall, G Ragnarson Tennvall, et al.
Clinical and Experimental Immunology|April 16, 2008
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudyC T Burton, R L Goodall, A Samri, et al.
Autophagy|June 1, 2014
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenibMegan L Goodall, Tong Wang, Katie R Martin, et al.
PLOS Global Public Health|February 10, 2026
QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trialGareth Hughes, Elena Frangou, Henry Bern, et al.
Journal of Environmental Management|August 5, 2023
Assessing and improving the outcomes of nonpoint source water quality trading policies in urban areas: A case study in VirginiaLinnea Saby, R Seth Herbst, Jonathan L Goodall, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringD T Dunn, R L Goodall, P Munderi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapyRavindra K Gupta, Ruth L Goodall, Michael Ranopa, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Antimicrobial Chemotherapy|May 1, 1999
Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?P J Easterbrook, R L Goodall, A G Babiker, et al.
Expert Opinion on Drug Safety|March 11, 2024
T-wave morphology abnormalities in the STREAM stage 1 trialGareth Hughes, William J Young, Henry Bern, et al.
AIDS Research and Human Retroviruses|October 9, 1998
Association between a defective CCR-5 gene and progression to disease in HIV infectionP Balfe, Y Churcher, M Penny, et al.
Sexually Transmitted Infections|August 7, 2003
Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital wartsC J N Lacey, R L Goodall, G Ragnarson Tennvall, et al.
Clinical and Experimental Immunology|April 16, 2008
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudyC T Burton, R L Goodall, A Samri, et al.
Autophagy|June 1, 2014
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenibMegan L Goodall, Tong Wang, Katie R Martin, et al.
PLOS Global Public Health|February 10, 2026
QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trialGareth Hughes, Elena Frangou, Henry Bern, et al.
Journal of Environmental Management|August 5, 2023
Assessing and improving the outcomes of nonpoint source water quality trading policies in urban areas: A case study in VirginiaLinnea Saby, R Seth Herbst, Jonathan L Goodall, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringD T Dunn, R L Goodall, P Munderi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2013
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapyRavindra K Gupta, Ruth L Goodall, Michael Ranopa, et al.
Pageof 9